Moderna (NASDAQ: MRNA) shareholders have been having a rough time lately. The biotech stock rocketed higher last spring, but ...

The messenger RNA (mRNA) pioneer provided a business and pipeline update at the J.P. Morgan Healthcare Conference on Monday.

Young biotech Dropshot Therapeutics has hooked in Etherna Immunotherapies with an RNA pact that could net up to $950 million.

Stéphane Bancel, CEO of mRNA specialist Moderna, delivered some difficult truths to shareholders about the company’s ...

Moderna now expects 2025 revenue to come in between $1.5 billion and $2.5 billion, most of which will come in the second half ...

Key Takeaways The S&P 500 ended 0.2% higher on Monday, Jan. 13, 2025, ahead of this week's inflation data and the first wave ...

Annemarie Hanekamp has overseen some of the most transformative changes in oncology over her years in Big Pharma. Now, she ...

The biotech company said it anticipates between $1.5 billion and $2.5 billion in revenue this year, below Wall Street ...

The biotech’s efforts to bring its vaccines to the country mean navigating political pushback in the U.S. and the risk of ...

Moderna (NASDAQ: MRNA) was one of the hottest companies of early pandemic times, delivering a coronavirus vaccine to market ...

Combining human efforts, nature, and AI in what Noubar Afeyan calls “polyintelligence” could solve problems such as climate ...